�Isolagen(TM), Inc. (Amex:
ILE) announced results from a prospective, subject label, Phase II study
(IT-R-007) of Isolagen Therapy(TM) for the treatment of facial wrinkles and
creases in some 40 subjects. Study subjects received deuce
treatments of Isolagen Therapy in multiple facial regions ("full face")
approximately basketball team weeks aside. The sketch results reported improvement in
the appearance of wrinkles as scored by a high portion both of study
subjects as well as of independent venire evaluators. The study results also
reported improvement in skin quality as scored by a high percentage of both
study subjects and active investigators.
Six months following their final treatment ("the six-month clock time
point"), 83 percent of subjects reported an advance in their
self-assessed musical score of the appearance of their wrinkles. This scale was the
same as the unitary used in the of late completed Isolagen Therapy pivotal
efficacy studies (IT-R-005 and -006). At the six-month time point, the
results from the independent gore evaluation of study photographs also
showed improvement in the appearance of wrinkles, with the independent
panel scoring melioration in over 75 percentage of participants.
"We are very pleased with the outcome of this explorative study," said
Declan Daly, President and Chief Executive Officer of Isolagen. "We are
peculiarly interested in the responses around cutis quality, as this is
the number 1 time we have assessed the Isolagen Therapy for these authoritative
skin characteristics."
Study IT-R-007 Study Results
As seen in all previous studies of Isolagen Therapy, treatment was very
intimately tolerated in Study IT-R-007. No serious adverse events related to the
Isolagen Therapy were observed.
Efficacy results from the trial showed that 83 per centum of study
subjects reported improvement in the appearance of their wrinkles victimization a
matter assessed, five-point response scale that ranged from "very
dissatisfied" to "very satisfied." Improvement was defined as a one point
act on the scale. The subject appraisal scale is the same scale used in
the recently realized IT-R-005 and 006 polar Phase III studies of
Isolagen Therapy.
The survey results as well included assessments from an independent panel
of three aesthetic dermatologists and formative surgeons wHO were non
involved with the treatment of subjects in the study. Results from these
independent evaluations noted advance in the appearance of wrinkles in
more than 75 per centum of report subjects using an evaluator-assessed,
four-point shell developed for this study, ranging from "no improvement" to
"marked improvement." Improvements were assessed using photographs of
subjects taken at baseline and at the six-month metre point.
Study IT-R-007 too included an assessment of skin character of the study
subjects, comparing results from baseline to the final six-month visit.
Using a Skin Quality Assessment Tool developed for this study, 93 percent
of subjects said their skin quality improved. Additionally, more than 95
percent of subjects showed improvements in skin quality based on the
Treating Investigator Assessment. Subjects and treating investigators each
assessed eight peel characteristics normally seen as the nerve ages and
solar hurt increases. Skin quality characteristics assessed at baseline
and the last six-month visit were: mildness, suppleness, smoothness,
firmness, thickness, moistness, evenness in visual aspect and reinvigorated
appearance. While the Skin Quality Assessment tool is not validated,
Isolagen is evaluating this scale for future use.
"As the principal researcher in the Isolagen IT-R-007 trial, I am
affirmative about the study results which indicate improvement in patients'
facial appearance," aforementioned Dr. Girish Munavalli, Assistant Professor of
Dermatology at Johns Hopkins School of Medicine. "The results suggest that
improvements in both skin texture and contour may be achieved following
Isolagen treatment. I believe this result is a unique finding in the
cosmetic injectable treatment market place, utilizing the subject's possess living
cells to provide the basis for advance."
Conducted at five US sites, the primary objectives of Study IT-R-007
were to assess the safety and efficacy of the Isolagen Therapy. In this
open label study, all subjects received the Isolagen Therapy and there was
no placebo control.
The Isolagen Process(TM) is a proprietary cellular processing system
that creates a natural, living cell therapy. By multiplying a person's have
collagen-producing cells, or fibroblasts, into tens of millions of new
cells, a personalized treatment is created that is then returned to the
person's cutis. This number 1 of its kind esthetic treatment, known as the
Isolagen Therapy, is designed to meliorate skin price caused by the normal
effects of aging, sun damage, acne and burns.
About Isolagen, Inc.
Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company
committed to developing and commercializing scientific advances and
innovative technologies. The company's technology platform includes the
Isolagen Process(TM), a cell processing system of rules for peel and tissue
rejuvenation which is presently in clinical development for a broad range
of aesthetic and therapeutic applications including wrinkles, acne scars,
burns and periodontal disease. Isolagen too commercializes a
scientifically-advanced dividing line of skin care systems through its majority-owned
subsidiary, Agera(R) Laboratories, Inc. For extra information, please
visit http://www.isolagen.com.
Isolagen Forward Looking Statements
All statements in this news program release that are non based on historical
fact are "innovative statements" inside the substance of the Private
Securities Litigation Reform Act of 1995 and the provisions of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. While management has based whatsoever
forward-looking statements contained herein on its current expectations,
the information on which such expectations were based may change. These
innovative statements swear on a number of assumptions concerning
future events and are subject to a number of risks, uncertainties, and
other factors, many of which are outside of our control, that could cause
actual results to materially take issue from such statements. Such risks,
uncertainties, and former factors include, but are not necessarily limited
to, those jell forth under Item 1A "Risk Factors" in the Company's Annual
Report on Form 10-K for the year complete December 31, 2007, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We
manoeuvre in a highly competitive and speedily changing environment, thus fresh
or out of the blue risks may arise. Accordingly, investors should not place any
reliance on innovative statements as a prevision of actual results.
We disclaim whatsoever intention to, and undertake no obligation to, update or
retool any forward-looking statements. Readers are too urged to carefully
review and consider the other various disclosures in the Company's Annual
Report on Form 10-K for the year complete December 31, 2007, as well as other
public filings with the SEC since such date.
Isolagen(TM), Inc.
http://www.isolagen.com
More information
Wednesday, 3 September 2008
Sunday, 24 August 2008
New Data Support Role For Monitoring Of Cell-Mediated Immunity In Adult Patients Following Renal Transplantation
�A late published article by
Sanchez-Velasco et al. in Clinical Transplantation has expanded our
understanding of the clinical potential of monitoring cell-mediated
immunity in adult patients at risk for organ rejection or infection
subsequent to kidney transplantation.
Pablo Sanchez-Velasco and his colleagues in the Cantabria Health System
and at the University of Cantabria, in Santander, Spain, used the Cylex
ImmuKnow assay to prospectively monitor intracellular adenosine
triphosphate (ATP) concentrations following CD4 cell activation as a
amount of cell mediated immune function in 81 immunosuppressed adults wHO
underwent kidney transplantation. The objective of their study was to
examine the association between cell-mediated immunity and risk for hammond organ
rejection (in under- immunosuppressed patients) or systemic infection (in
over-immunosuppressed patients). Their data were also compared to
intracellular ATP levels in 52 (non-transplanted) healthy controls.
Their results demonstrated a clear correlation betwixt intracellular
ATP levels for the goodish control mathematical group, a group of stable transplant
patients, and infected transplant patients, with a statistically
meaning difference betwixt the average ATP levels for these three
groups:
-- Infected transplant group (n = 24): mean ATP level = 197 +/- 114 ng/mL
-- Stable transpose group (n = 54): mean ATP level = 313 +/- 193 ng/mL
-- Healthy control radical (n = 52): beggarly ATP horizontal surface = 409 +/- 177 ng/mL
Only trio patients in this trial underwent an acute rejection episode
during the course of this study. The authors state that this was an
insufficient number of patients to formalise the part of the ImmuKnow assay
in monitoring risk for organ rejection. The hateful ATP layer of the three
patients who underwent acute organ rejection was 247 +/- 193 ng/mL.
"We ar pleased to see the data from this study support to begin with
published data on the use of the ImmuKnow assay in monitoring adult
patients later on a nephritic transplant," declared Brad L. Stewart, president of
Cylex. "Clearly there is farther research requisite to shed light on the
seize standards for use of cell-mediated immunity to monitor risk for
infection and rejection in selected patient categories. However, this
publication further illustrates the potency risks for infection
associated with over-immunosuppression in renal transplant patients, and
the potential economic value of the ImmuKnow assay in monitoring immune condition."
Sanchez-Velasco P, Rodrigo E, Valero R, et al. Intracellular ATP
concentrations of CD4 cells in kidney transplant patients with and without
infection. Clin Transplant. 2008;22:55-60.
About ImmuKnow(R)
ImmuKnow is the immune cell function assay clear by the FDA to detect
cell-mediated immunity (CMI) in adult patient populations undergoing
immunosuppressive therapy for organ transplantation by measure the
assiduousness of adenosine triphosphate (ATP) released from CD4 cells
following cell stimulation.
The ImmuKnow test is a qualitative assay and does not directly quantify
the level of immunosuppression. Results of ImmuKnow assays should be secondhand
in conjunction with clinical presentation, aesculapian history, and other
clinical indicators when assessing the immune status of whatsoever individual
patient. The uses of the ImmuKnow assay as described in these studies get
not been approved or cleared by the FDA. The Company may use data from
these or similar studies to support future FDA marketing applications for
similar indications.
About Cylex, Inc.
Cylex(TM) is a privately held global life sciences company that is the
loss leader in the development and manufacture of in vitro diagnostic products
intended to illuminate immunity. The Company's patented engineering provides
an innovative platform allowing clinical researchers to simply and
reproducibly bar immune cell function for the evolution of new
diagnostics, biomarkers, and comrade assays. The Company is based in
Columbia, MD, USA.
Cylex(TM)
http://www.cylex.net
More info
Sanchez-Velasco et al. in Clinical Transplantation has expanded our
understanding of the clinical potential of monitoring cell-mediated
immunity in adult patients at risk for organ rejection or infection
subsequent to kidney transplantation.
Pablo Sanchez-Velasco and his colleagues in the Cantabria Health System
and at the University of Cantabria, in Santander, Spain, used the Cylex
ImmuKnow assay to prospectively monitor intracellular adenosine
triphosphate (ATP) concentrations following CD4 cell activation as a
amount of cell mediated immune function in 81 immunosuppressed adults wHO
underwent kidney transplantation. The objective of their study was to
examine the association between cell-mediated immunity and risk for hammond organ
rejection (in under- immunosuppressed patients) or systemic infection (in
over-immunosuppressed patients). Their data were also compared to
intracellular ATP levels in 52 (non-transplanted) healthy controls.
Their results demonstrated a clear correlation betwixt intracellular
ATP levels for the goodish control mathematical group, a group of stable transplant
patients, and infected transplant patients, with a statistically
meaning difference betwixt the average ATP levels for these three
groups:
-- Infected transplant group (n = 24): mean ATP level = 197 +/- 114 ng/mL
-- Stable transpose group (n = 54): mean ATP level = 313 +/- 193 ng/mL
-- Healthy control radical (n = 52): beggarly ATP horizontal surface = 409 +/- 177 ng/mL
Only trio patients in this trial underwent an acute rejection episode
during the course of this study. The authors state that this was an
insufficient number of patients to formalise the part of the ImmuKnow assay
in monitoring risk for organ rejection. The hateful ATP layer of the three
patients who underwent acute organ rejection was 247 +/- 193 ng/mL.
"We ar pleased to see the data from this study support to begin with
published data on the use of the ImmuKnow assay in monitoring adult
patients later on a nephritic transplant," declared Brad L. Stewart, president of
Cylex. "Clearly there is farther research requisite to shed light on the
seize standards for use of cell-mediated immunity to monitor risk for
infection and rejection in selected patient categories. However, this
publication further illustrates the potency risks for infection
associated with over-immunosuppression in renal transplant patients, and
the potential economic value of the ImmuKnow assay in monitoring immune condition."
Sanchez-Velasco P, Rodrigo E, Valero R, et al. Intracellular ATP
concentrations of CD4 cells in kidney transplant patients with and without
infection. Clin Transplant. 2008;22:55-60.
About ImmuKnow(R)
ImmuKnow is the immune cell function assay clear by the FDA to detect
cell-mediated immunity (CMI) in adult patient populations undergoing
immunosuppressive therapy for organ transplantation by measure the
assiduousness of adenosine triphosphate (ATP) released from CD4 cells
following cell stimulation.
The ImmuKnow test is a qualitative assay and does not directly quantify
the level of immunosuppression. Results of ImmuKnow assays should be secondhand
in conjunction with clinical presentation, aesculapian history, and other
clinical indicators when assessing the immune status of whatsoever individual
patient. The uses of the ImmuKnow assay as described in these studies get
not been approved or cleared by the FDA. The Company may use data from
these or similar studies to support future FDA marketing applications for
similar indications.
About Cylex, Inc.
Cylex(TM) is a privately held global life sciences company that is the
loss leader in the development and manufacture of in vitro diagnostic products
intended to illuminate immunity. The Company's patented engineering provides
an innovative platform allowing clinical researchers to simply and
reproducibly bar immune cell function for the evolution of new
diagnostics, biomarkers, and comrade assays. The Company is based in
Columbia, MD, USA.
Cylex(TM)
http://www.cylex.net
More info
Thursday, 14 August 2008
Medarex Announces Initiation Of Phase 2 Clinical Development Program For The Treatment Of Lupus
�Medarex, Inc.
(Nasdaq: MEDX) announced that its partner MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the
potential discourse of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development System(R). Under the damage of the agreement, Medarex
will receive a milestone payment of an undisclosed amount.
The Phase 2A clinical visitation is intentional to assess the safety and
tolerability of multiple subcutaneous vD schedules of MEDI-545 or placebo
in adult patients with moderate to terrible active lupus. The study will also
assess the effects of MEDI-545 on disease activity in lupus patients. This
randomized, double blind, placebo-controlled trial is expected to recruit 80
patients and will be conducted at 20 sites in the United States.
MedImmune is likewise conducting a Phase 1 clinical run for MEDI-545 in
idiopathic inflammatory myositis, an immunological disease that involves
chronic muscle firing, pain and weakness.
"Data from an earlier reported placebo-controlled Phase 1 report
suggested therapeutical activity with single doses in patients with lupus and
demonstrated an acceptable safety profile," said Geoffrey M. Nichol,
M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are
very excited about the role of the interferon alpha inflammatory nerve pathway
and look forward to exploring its potential in treating patients with lupus
and other autoimmune diseases."
About MEDI-545
MEDI-545 (previously known as MDX-1103) is a fully human monoclonal
antibody targeting interferon-alpha. Published information indicate that levels of
interferon-alpha are elevated in many patients with active SLE and other
autoimmune disorders, and may be associated with disease activity.
Preclinical information from creature models indicate that MEDI-545 may suppress the
abnormal immune action associated with lupus by binding to multiple
interferon-alpha subtypes seen in the serum of lupus patients.
In November 2004, MedImmune entered into a collaboration with Medarex
to focus on two specific antibodies, one of which was MDX-1103 (now known
as MEDI-545). Under the price of the agreement, MedImmune is responsible
for all ongoing clinical development activities. Prior to the beginning of
polar studies, Medarex may elect to co-develop the products in return for
the opportunity to co-promote and to get a parcel of the commercial
lucre in the United States. In all other cases, Medarex will be entitled
to get milestone payments and royalties.
About Lupus
Approximately 350,000 individuals in the United States are affected
with lupus, a chronic inflammatory disease that causes the body to attack
its own tissues and organs, including the skin, joints, blood and kidneys.
Treatments for lupus include anti-inflammatory drug drugs, antimalarials,
corticosteroids and drugs approved for other purposes, such as
immunosuppressant agents granted to genus Cancer patients undergoing chemotherapy
or medicines developed to process arthritis patients. Lupus occurs about 10
times more frequently in adult females than adult males, and is two to
deuce-ace times more common among African Americans, Hispanics, Asians and
Native Americans.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
maturation and potentiality commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
malignant neoplastic disease, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing have to generate, support and potentially commercialise
a full range of fully human antibody product candidates for itself and its
partners. More than 40 of these healing product candidates derived from
Medarex applied science are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the theme of regulative
applications for marketing authorisation. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more selective information about Medarex, visit
its website at http://www.medarex.com.
Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed herein may constitute forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, that are national to
certain risks and uncertainties that could causa actual results to take issue
materially from any future results, performance or achievements expressed
or implied by such statements. Statements that are non historical facts,
including statements preceded by, followed by, or that include the words
"expect"; "potential" or "may"; or similar statements are advanced
statements. Medarex disclaims, however, any intent or indebtedness to update
these forward-looking statements. Risks and uncertainties include
uncertainties related to the result of clinical trials, slower than
expected rates of patient recruitment, unforeseen base hit issues resulting
from the administration of MEDI-545 in patients, as well as risks elaborate
from metre to time in Medarex's public revealing filings with the U.S.
Securities and Exchange Commission (SEC), including its Annual Report on
Form 10-K for the fiscal year ended December 31, 2007 and its quarterly
reports on Form 10-Q. There can be no pledge that such development
efforts will come through or that other developed products volition receive compulsory
regulatory clearance or that, even if such regulative clearance were
received, such products would ultimately attain commercial success. Copies
of Medarex's world disclosure filings are useable from its investor
relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved
Medarex, Inc.
http://www.medarex.com
More info
(Nasdaq: MEDX) announced that its partner MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the
potential discourse of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development System(R). Under the damage of the agreement, Medarex
will receive a milestone payment of an undisclosed amount.
The Phase 2A clinical visitation is intentional to assess the safety and
tolerability of multiple subcutaneous vD schedules of MEDI-545 or placebo
in adult patients with moderate to terrible active lupus. The study will also
assess the effects of MEDI-545 on disease activity in lupus patients. This
randomized, double blind, placebo-controlled trial is expected to recruit 80
patients and will be conducted at 20 sites in the United States.
MedImmune is likewise conducting a Phase 1 clinical run for MEDI-545 in
idiopathic inflammatory myositis, an immunological disease that involves
chronic muscle firing, pain and weakness.
"Data from an earlier reported placebo-controlled Phase 1 report
suggested therapeutical activity with single doses in patients with lupus and
demonstrated an acceptable safety profile," said Geoffrey M. Nichol,
M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are
very excited about the role of the interferon alpha inflammatory nerve pathway
and look forward to exploring its potential in treating patients with lupus
and other autoimmune diseases."
About MEDI-545
MEDI-545 (previously known as MDX-1103) is a fully human monoclonal
antibody targeting interferon-alpha. Published information indicate that levels of
interferon-alpha are elevated in many patients with active SLE and other
autoimmune disorders, and may be associated with disease activity.
Preclinical information from creature models indicate that MEDI-545 may suppress the
abnormal immune action associated with lupus by binding to multiple
interferon-alpha subtypes seen in the serum of lupus patients.
In November 2004, MedImmune entered into a collaboration with Medarex
to focus on two specific antibodies, one of which was MDX-1103 (now known
as MEDI-545). Under the price of the agreement, MedImmune is responsible
for all ongoing clinical development activities. Prior to the beginning of
polar studies, Medarex may elect to co-develop the products in return for
the opportunity to co-promote and to get a parcel of the commercial
lucre in the United States. In all other cases, Medarex will be entitled
to get milestone payments and royalties.
About Lupus
Approximately 350,000 individuals in the United States are affected
with lupus, a chronic inflammatory disease that causes the body to attack
its own tissues and organs, including the skin, joints, blood and kidneys.
Treatments for lupus include anti-inflammatory drug drugs, antimalarials,
corticosteroids and drugs approved for other purposes, such as
immunosuppressant agents granted to genus Cancer patients undergoing chemotherapy
or medicines developed to process arthritis patients. Lupus occurs about 10
times more frequently in adult females than adult males, and is two to
deuce-ace times more common among African Americans, Hispanics, Asians and
Native Americans.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
maturation and potentiality commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
malignant neoplastic disease, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing have to generate, support and potentially commercialise
a full range of fully human antibody product candidates for itself and its
partners. More than 40 of these healing product candidates derived from
Medarex applied science are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the theme of regulative
applications for marketing authorisation. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more selective information about Medarex, visit
its website at http://www.medarex.com.
Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed herein may constitute forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, that are national to
certain risks and uncertainties that could causa actual results to take issue
materially from any future results, performance or achievements expressed
or implied by such statements. Statements that are non historical facts,
including statements preceded by, followed by, or that include the words
"expect"; "potential" or "may"; or similar statements are advanced
statements. Medarex disclaims, however, any intent or indebtedness to update
these forward-looking statements. Risks and uncertainties include
uncertainties related to the result of clinical trials, slower than
expected rates of patient recruitment, unforeseen base hit issues resulting
from the administration of MEDI-545 in patients, as well as risks elaborate
from metre to time in Medarex's public revealing filings with the U.S.
Securities and Exchange Commission (SEC), including its Annual Report on
Form 10-K for the fiscal year ended December 31, 2007 and its quarterly
reports on Form 10-Q. There can be no pledge that such development
efforts will come through or that other developed products volition receive compulsory
regulatory clearance or that, even if such regulative clearance were
received, such products would ultimately attain commercial success. Copies
of Medarex's world disclosure filings are useable from its investor
relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved
Medarex, Inc.
http://www.medarex.com
More info
Friday, 27 June 2008
Thursday, 19 June 2008
Tomie Nevada
Artist: Tomie Nevada
Genre(s):
Techno
Discography:
Meeting at the Cornfields EP
Year: 2005
Tracks: 2
Friday, 13 June 2008
Tunstall's Orpheum show: All that with 'Cherry' on top
A little versatility goes a long way. This is especially true in today’s music market, which is drowning in mediocre singer/songwriters.
But an artist can distinguish herself from the herd by demonstrating a wealth of musical possibilities. Scottish firecracker KT Tunstall did just that at the Orpheum last night with an unplugged set that yielded marvelous results.
Tunstall opened with “Miniature Disasters,” a sturdy tune built of chunky riffs from her 2004 debut, “Eye to the Telescope.” But more revealing was how well “Little Favours,” from her latest CD “Drastic Fantastic,” lent itself to the pared-down motif. That the song came across as stunningly as it did minus the new CD’s slick production value attests to the durability of Tunstall’s songwriting. Playing a 12-string guitar, her vocals portrayed road-worn huskiness and a bit of Americana-styled grit, but she remained flexible; during the tender reading of “Other Side of the World” she hit all the high notes.
Her four-piece band improvised ingeniously on Tunstall’s material: keyboardist Kenny Dickenson played marimba on the recent single “Hold On,” and added a muted horn solo to the New Orleans-meets-Nashville feel of “Ashes.” Bassist Arnulf Lindner contributed a colorful kazoo to “Funnyman,” which also found guitarist Sam Lewis switching to mandolin duties, which he reprised during a klutzy but well-intentioned encore cover of Rufus and Chaka Khan’s “Ain’t Nobody.”
A holdover from her early solo shows, Tunstall made good use of her loop-and-pedal skills, building “Black Horse & the Cherry Tree” from the ground up while the crowd cheered her on. During the latter half of “Beauty of Uncertainty” she used the same trick to cook up a flesh-raising layered vocal.
The Orpheum wasn’t quite full for her Boston return, and “Drastic Fantastic” hasn’t sold nearly as well as her debut. But, dressed in a white V-neck T-shirt, skin-tight black jeans with boots and hoop earrings, Tunstall seemed not to care. And while those who came looking for a full-on rock show were likely disappointed, she owes no apologies for switching things up; on the contrary, being able to change gears will help keep her in the game.
Accompanied only by his guitar and guest keyboardist/vocalist Fiona Melady, Irish lad Paddy Casey opened with a set of passionately sung numbers that revealed capable pipes and a penchant for palatable melancholy.
ctreacy2003@yahoo.com
But an artist can distinguish herself from the herd by demonstrating a wealth of musical possibilities. Scottish firecracker KT Tunstall did just that at the Orpheum last night with an unplugged set that yielded marvelous results.
Tunstall opened with “Miniature Disasters,” a sturdy tune built of chunky riffs from her 2004 debut, “Eye to the Telescope.” But more revealing was how well “Little Favours,” from her latest CD “Drastic Fantastic,” lent itself to the pared-down motif. That the song came across as stunningly as it did minus the new CD’s slick production value attests to the durability of Tunstall’s songwriting. Playing a 12-string guitar, her vocals portrayed road-worn huskiness and a bit of Americana-styled grit, but she remained flexible; during the tender reading of “Other Side of the World” she hit all the high notes.
Her four-piece band improvised ingeniously on Tunstall’s material: keyboardist Kenny Dickenson played marimba on the recent single “Hold On,” and added a muted horn solo to the New Orleans-meets-Nashville feel of “Ashes.” Bassist Arnulf Lindner contributed a colorful kazoo to “Funnyman,” which also found guitarist Sam Lewis switching to mandolin duties, which he reprised during a klutzy but well-intentioned encore cover of Rufus and Chaka Khan’s “Ain’t Nobody.”
A holdover from her early solo shows, Tunstall made good use of her loop-and-pedal skills, building “Black Horse & the Cherry Tree” from the ground up while the crowd cheered her on. During the latter half of “Beauty of Uncertainty” she used the same trick to cook up a flesh-raising layered vocal.
The Orpheum wasn’t quite full for her Boston return, and “Drastic Fantastic” hasn’t sold nearly as well as her debut. But, dressed in a white V-neck T-shirt, skin-tight black jeans with boots and hoop earrings, Tunstall seemed not to care. And while those who came looking for a full-on rock show were likely disappointed, she owes no apologies for switching things up; on the contrary, being able to change gears will help keep her in the game.
Accompanied only by his guitar and guest keyboardist/vocalist Fiona Melady, Irish lad Paddy Casey opened with a set of passionately sung numbers that revealed capable pipes and a penchant for palatable melancholy.
ctreacy2003@yahoo.com
Saturday, 7 June 2008
Gin Blossoms
Artist: Gin Blossoms
Genre(s):
Rock
Rock: Pop-Rock
Other
Discography:
Major Lodge Victory
Year: 2006
Tracks: 12
Outside Looking in
Year: 1999
Tracks: 14
New Miserable Experience
Year: 1997
Tracks: 12
Congratulations I'm Sorry
Year: 1996
Tracks: 13
Dusted
Year: 1989
Tracks: 12
Up and Crumbling
Year:
Tracks: 5
Alternative magnate popsters Gin Blossoms were formed in 1987 in Tempe, AZ, by longtime friends Bill Leen (bass) and Doug Hopkins (guitar), with an initial batting order besides featuring vocalist Jesse Valenzuela, guitarist Richard Taylor, and drummer Chris McCann. The following year power saw several personnel office shifts as the band struggled to solidify -- McCann was replaced by Dan Henzerling and, shortly thenceforth, Phillip Rhodes, while Taylor was laid-off and replaced by guitar player Robin Wilson. Wilson and Valenzuela after switched roles, and the band recorded a self-released record album, Dusted, in 1989. A&M signed them the next year.
Later an telling 1991 debut EP, Up & Crumbling, the Gin Blossoms rocketed out of the college pop charts and into the mainstream with their 1993 hit unmarried "Hey Jealousy." Combining the vibrancy guitar hooks of the Byrds and R.E.M. with a square, rootsy drive, the band's breakthrough full-length album, Modern Miserable Experience (which had actually been released the old year), was filled with songs equally as impregnable as "Hey Jealousy," including the sec strike single, "Establish Out About You." New Miserable Experience and its singles henpecked radio and MTV for the following year -- "Hey Jealousy" and "Establish Out About You," both penned by Hopkins, were in lumbering radiocommunication rotation nigh a year subsequently their initial sack -- pushing the sales of their debut album to over one billion copies.
However, all was non intimately. Hopkins' struggle with alcoholism and depression had taken its toll on the band during the sessions for New Miserable Experience, and he was laid-off shortly subsequently the record's release, with guitar player Scott Johnson pickings his station. Speculation abounded as to whether the band would be capable to wield their success without Hopkins' black bile songwriting voice. Tragically, on December 5, 1993, Hopkins stroke and killed himself, regular as the songs he had scripted were blanketing the airwaves.
In the summertime of 1995, the Gin Blossoms contributed "'Till I Hear It from You," a song they co-wrote with Marshall Crenshaw, to the soundtrack of the plastic film Empire Records. "'Till I Hear It from You" became a major radiocommunication hit, merely was never released as an official individual until it was the B-side of "Follow You Down," the showtime undivided from the group's second record album, Congratulations...I'm Sorry. Upon its release in February of 1996, Praise...I'm Sorry charted well, merely inside sixer months, it had disappeared from the charts. Following the encouraging circuit, the Gin Blossoms disbanded in 1997.
Queerly sufficiency, the group reunited sans Rhodes on New Years Eve of 2001 for a concert. Deciding to arrange themselves back together for a spell, the band hit the road a few months later in the summertime of 2002 and released a alive DVD that fall to prepare audiences for a new album, Dusted, which was followed little Joe eld later with Major Lodge Victory.
Lohan to work in morgue as punishment
Subscribe to:
Comments (Atom)